February 25, 2013. Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesions. [ Read more ]
June 2010. AsymmetRx Medical, Inc. a Boston based Biotechnology Company, announced the signing of a license agreement with Ventana Medical, A member of the Roche Group. This agreement provides Ventana with the exclusive license and distribution rights of their patented Prostate Cancer Diagnostic tool p63. [ Read more ]
November 2007. Third patent issues on the p63 gene and related antibodies.
May 2007. AsymmetRx receives exclusive rights from Harvard relating to research use only portion of patents. AsymmetRx is the only licensee permitted to sublicense.
April 18, 2006. Second patent issues on p63 gene and related antibodies. The Patent and Trademark Office issued a second patent on the p63 gene, related antibodies, and methods. AsymmetRx has exclusive rights to the diagnostics under this patent.
October 24, 2005. Wall Street Journal recognizes the p63 technology as one of the best new innovations. [ Read more ]
September 20, 2005. Patent issues on p63 gene and related antibodies. The Patent and Trademark Office issued the patent on the p63 gene, related antibodies, and methods. AsymmetRx has exclusive rights to the diagnostics under this patent.
February 9, 2005. Washington, D.C. The Food and Drug Administration approved the Prostate-63 Cancer Diagnostic Test as a diagnostic test to detect prostate cancer. The test features a mouse monoclonal antibody, clone 4A4, that recognizes the human p63 protein in the nucleus of prostatic basal cells and urothelial tissues (Yang et al., 1998; Signoretti et al., 2000). The bright staining of p63 provides for an easy diagnosis of prostate cancer. [ Read more ]
January 27, 2005. Baltimore, MD Johns Hopkins University grants AsymmetRx, Inc. exclusive rights to angiogenesis technology and targets. The technology allows one to quickly scan FDA approved drugs for alternative uses. A number of drug targets have been identified using this technology, including targets for cancer treatment and macular degeneration.
June 30, 2004. Boston, MA Harvard University grants AsymmetRx, Inc. exclusive rights to p63 gene and antibodies associated with the prostate cancer gene. p-63 gene was discovered in Founder Frank McKeon’s lab at Harvard and the antibody was developed to diagnose prostate cancer on biopsied tissue. AsymmetRx, Inc. has exclusive rights to all diagnostic use of the gene and the associated antibodies.